Pulse Biosciences
Pulse Biosciences

Pulse Biosciences

Health Care Equipment & Supplies
WebsiteInvestor RelationsSEC
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.

$3.8B

Market Cap • 9/11/2026

2014

(12 years)

Founded

2016

(10 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

38

P/S

3189,1

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

1,5

EPS

—

Market Cap

Market Cap

3,8B

EV

3,7B

EV/Revenue

3109

EV/EBITDA

-44,9

EV/EBIT

-44,4

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-1,5%

Total Yield

-1,5%

Payout

0%

Retained Earnings

-506,5M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

4378,6%

Capex/Revenue

24,5%

Capex/D&A

28,3%

Capex/OCF

-0,5%

SBC/OCF

—

% PPE

5,6%

% Goodwill

2,4%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

6,7%

CAGR Net Income 5Y

4,3%

CAGR EPS 5Y

-12,8%

CAGR OCF 5Y

5,9%

Leverage

N.D./EBITDA

1,2

Debt/Equity

0%

Current Ratio

9,6

Quick Ratio

9,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium